Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alteration in estrogen receptor status in metachronous contralateral breast cancer among unilateral early breast cancer patients with BRCA 1/2 mutations.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology - 1 Feb 2026

Kim Ki Jo, Kang Eunhye, Baek Seung Ho, Lee Han-Byoel, Ahn Sung Gwe, Park Woong Ki, Shin Dong Seung, Lee Hyunwoo, Nam Seok Jin, Kim Seok Won, Yu Jong Han, Chae Byung Joo, Lee Se Kyung, Lee Jeong Eon, Ryu Jai Min

Abstract excerpt

BACKGROUND: BRCA1/2 mutations significantly increase the risk of contralateral breast cancer (CBC). However, their influence on estrogen receptor (ER) status changes between primary breast cancer and metachronous CBC remains unclear. This study investigates ER status alterations in CBC patients with BRCA1/2 mutations to clarify their clinical implications. METHODS: In this multicenter retrospective study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Breast Neoplasms

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Neoplasms, Second Primary

Share to Receptors, Estrogen

Source

Identifiers

PMID: 41352331
DOI: 10.1016/j.ejso.2025.111332

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alteration in estrogen receptor status in metachronous contralateral breast cancer among unilateral early breast cancer patients with BRCA 1/2 mutations.PMID 41352331Read ↗

Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.Semantic proximity Read ↗

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study.Semantic proximity Read ↗

Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.Semantic proximity Read ↗

The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.Semantic proximity Read ↗

Tumor phenotype and concordance in synchronous bilateral breast cancer in young women.Semantic proximity Read ↗

Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.Semantic proximity Read ↗

Contralateral breast cancer and tumor recurrence in BRCA1/2 carriers and non-carriers at a high risk of hereditary breast cancer after bilateral mastectomy.Semantic proximity Read ↗

Bilateral breast cancers.Semantic proximity Read ↗

A study of clinical and molecular characteristics in bilateral primary breast cancer.Semantic proximity Read ↗

Survival Outcomes in Women with Unilateral, Triple-Negative, Breast Cancer Correlated with Contralateral Prophylactic Mastectomy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.